Sergi D, Zauli E, Tisato V, Secchiero P, Zauli G, Cervellati C
Int J Mol Sci. 2023; 24(5).
PMID: 36901834
PMC: 10002119.
DOI: 10.3390/ijms24054403.
Denimal D, Monier S, Bouillet B, Verges B, Duvillard L
Metabolites. 2023; 13(2).
PMID: 36837872
PMC: 9967905.
DOI: 10.3390/metabo13020253.
Vyletelova V, Novakova M, Paskova L
Pharmaceuticals (Basel). 2022; 15(10).
PMID: 36297390
PMC: 9611871.
DOI: 10.3390/ph15101278.
Diab A, Valenzuela Ripoll C, Guo Z, Javaheri A
Front Cardiovasc Med. 2022; 9:846990.
PMID: 35350538
PMC: 8958020.
DOI: 10.3389/fcvm.2022.846990.
Cochran B, Ong K, Manandhar B, Rye K
Cells. 2021; 10(4).
PMID: 33918571
PMC: 8069617.
DOI: 10.3390/cells10040850.
HDL and Reverse Cholesterol Transport.
Ouimet M, Barrett T, Fisher E
Circ Res. 2019; 124(10):1505-1518.
PMID: 31071007
PMC: 6813799.
DOI: 10.1161/CIRCRESAHA.119.312617.
Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation.
Ito F, Sono Y, Ito T
Antioxidants (Basel). 2019; 8(3).
PMID: 30934586
PMC: 6466575.
DOI: 10.3390/antiox8030072.
Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus.
Dullaart R, Pagano S, Perton F, Vuilleumier N
Int J Mol Sci. 2019; 20(3).
PMID: 30744100
PMC: 6387386.
DOI: 10.3390/ijms20030732.
Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.
Gourgari E, Playford M, Campia U, Dey A, Cogen F, Gubb-Weiser S
Cardiovasc Diabetol. 2018; 17(1):158.
PMID: 30567548
PMC: 6299549.
DOI: 10.1186/s12933-018-0802-0.
Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.
Kelesidis T, Kendall M, Danoff A, Aberg J, Currier J, Schmidt A
Medicine (Baltimore). 2018; 97(22):e10955.
PMID: 29851842
PMC: 6392937.
DOI: 10.1097/MD.0000000000010955.
The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.
Femlak M, Gluba-Brzozka A, Cialkowska-Rysz A, Rysz J
Lipids Health Dis. 2017; 16(1):207.
PMID: 29084567
PMC: 5663054.
DOI: 10.1186/s12944-017-0594-3.
Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.
Kashyap S, Osme A, Ilchenko S, Golizeh M, Lee K, Wang S
J Clin Endocrinol Metab. 2017; 103(2):388-396.
PMID: 29077935
PMC: 5800833.
DOI: 10.1210/jc.2017-01551.
Dietary Patterns and Cardiovascular Disease Risk in People with Type 2 Diabetes.
Archundia Herrera M, Subhan F, Chan C
Curr Obes Rep. 2017; 6(4):405-413.
PMID: 29063379
DOI: 10.1007/s13679-017-0284-5.
Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study.
Annema W, Dikkers A, de Boer J, van Greevenbroek M, van der Kallen C, Schalkwijk C
Sci Rep. 2016; 6:27367.
PMID: 27270665
PMC: 4897620.
DOI: 10.1038/srep27367.
Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report.
Apro J, Tietge U, Dikkers A, Parini P, Angelin B, Rudling M
Arterioscler Thromb Vasc Biol. 2016; 36(5):787-91.
PMID: 27034474
PMC: 4845764.
DOI: 10.1161/ATVBAHA.116.307385.
Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.
Lyons T, Jenkins A
Diabetes Rev (Alex). 2015; 5(4):365-391.
PMID: 26366051
PMC: 4567260.
Vascular Effects of Dietary Advanced Glycation End Products.
Stirban A, Tschope D
Int J Endocrinol. 2015; 2015:836498.
PMID: 26089897
PMC: 4451780.
DOI: 10.1155/2015/836498.
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.
Stirban A, Gawlowski T, Roden M
Mol Metab. 2014; 3(2):94-108.
PMID: 24634815
PMC: 3953708.
DOI: 10.1016/j.molmet.2013.11.006.
Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.
Brown B, Nobecourt E, Zeng J, Jenkins A, Rye K, Davies M
PLoS One. 2013; 8(5):e65430.
PMID: 23741493
PMC: 3669297.
DOI: 10.1371/journal.pone.0065430.
Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.
Kurosaki Y, Tsukushi T, Munekata S, Akahoshi T, Moriya T, Ogawa Z
J Clin Lab Anal. 2013; 27(3):231-6.
PMID: 23440769
PMC: 6807556.
DOI: 10.1002/jcla.21591.